MTOR and neoplasm: Concerning TME biology and its potential role as a therapeutic target, the balance between different T cell subsets and recruitment and activation of immunosuppressive myeloid subsets can be altered by multiple tumor-derived factors released in the context of TME, resulting in mTOR-mediated metabolic and transcriptional reprogramming and the establishment of inappropriate immune cell responses.